Sponsor

Galecto Biotech AB

Denmark Ole Maaloees Vej 3, 2200 Copenhagen, Denmark

About the sponsor

Clinical research in non-small cell lung cancer focuses on GB1211, a galectin-3 inhibitor, studied in combination with atezolizumab in patients with advanced disease. The programme examines antitumor activity, lesion response, and treatment-related safety in NSCLC.

Immuno-oncology combinations
Galectin-3 inhibition
Tumor response assessment
Long-term safety

This area reflects a focus on lung cancer therapies that integrate targeted pathways with immune checkpoint inhibition.

About Specializations

Galecto Biotech AB runs clinical trials in conditions such as Hepatic fibrosis, Non-small cell lung cancer, Non-small cell lung cancer stage IV, Non-small cell lung cancer stage IIIB, among others.

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Quick filters

2 clinical trials

Hepatic fibrosis+1

Not recruiting

InvestigationalNo placebo

Study comparing how the body processes GB1211 capsule and tablet forms with and without food in healthy volunteers

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · Healthy volunteers
Substances:2-(5-BROMOPYRIDIN-3-YL)SULFANYL-6-(HYDROXYMETHYL)-4-[4-(3,4,5-TRIFLUOROPHENYL)TRIAZOL-1-YL]OXANE-3,5-DIOL
Sponsor:Galecto Biotech AB